[无可用内容]。

[Not Available].

作者信息

Oudard Stéphane, Thibault Constance, Angelergues Antoine, Tartour Eric, Timsit Marc Olivier, Mejean Arnaud, Michel Constance, Vano Yann

机构信息

Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, Sorbonne-Paris-Cité, France; INSERM U970 PARCC université Paris-Descarte, Paris France.

Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France.

出版信息

Bull Cancer. 2016 Nov;103 Suppl 1:S144-S150. doi: 10.1016/S0007-4551(16)30372-1.

DOI:10.1016/S0007-4551(16)30372-1

PMID:28057178

Abstract

Immunotherapy is moving forward in prostate cancer. The autologous vaccine, Sipuleucel-T has been the first vaccine to be approved by FDA. First results with GVAX, tasquinimob or anti-PD-1 have been disappointing. Ipilimumab seen to be more active at an earlier stage of prostate disease. Identifying predictive factor or surrogate markers of activity of immunotherapy and which agents are clinically effective alone or in combination with others therapies such as hormonal or bone targeted therapies are warranted.

摘要

免疫疗法在前列腺癌治疗领域不断取得进展。自体疫苗西妥昔单抗-T是首个获美国食品药品监督管理局（FDA）批准的疫苗。GVAX、他喹莫博或抗程序性死亡蛋白1（anti-PD-1）的初步结果令人失望。伊匹单抗在前列腺疾病的早期阶段似乎更具活性。确定免疫疗法活性的预测因素或替代标志物，以及哪些药物单独使用或与其他疗法（如激素疗法或骨靶向疗法）联合使用具有临床疗效是很有必要的。